First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT ID: NCT04000282

Last Updated: 2025-09-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-08-19
• Study Completion Date: 2023-09-04

Brief Summary

Primary Objectives:

• Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B
• Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM

Secondary Objectives:

• To characterize the safety profile of SAR442085
• To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a single agent
• To evaluate the potential immunogenicity of SAR442085
• To assess preliminary evidence of antitumor activity in the Dose Escalation Part A

Detailed Description

Patient will continue to receive study medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason why investigator considers it appropriate to discontinue study medication. Once permanently discontinued, study medication cannot be restarted at later timepoint.

Conditions

Plasma Cell Myeloma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part A: SAR442085 dose escalation

SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.

Group Type: EXPERIMENTAL

SAR442085

Intervention Type: DRUG

Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous

Part B: SAR442085 dose expansion

SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.

Group Type: EXPERIMENTAL

SAR442085

Intervention Type: DRUG

Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous

Interventions

SAR442085

Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant must be at least 18 years of age or of the country's legal age of majority if the legal age is >18 years old, at the time of signing the informed consent.
• Participant has given voluntary written informed consent.
• Participant has been previousy diagnosed with multiple myeloma based on standard criteria.
• Part A: (1) participant has received at least 3 prior lines of therapy for multiple myeloma, or at least 2 prior lines of therapy if at least 1 of those lines consisted of 2 or more multi-agent regimens (eg, multi-agent induction regimen with autologous stem cell transplantation, followed by maintenance regimen). (2) Prior therapy for multiple myeloma has included at least 1 proteasome inhibitor (bortezomib, carfilzomib, ixazomib), at least 1 immunomodulatory agent (lenalidomide, thalidomide, pomalidomide), at least 1 anti-CD38 monoclonal antibody and at least 1 steroid. Applicable countries in EU and Asia can enroll anti-CD38 naive RRMM patients from DL4 and onwards. (3) Participant had at least a minimal response (MR) to the anti-CD38 antibody containing regimen and had last dose of anti-CD38 monoclonal antibody at least 9 months prior to study entry. Applicable countries in EU and Asia can enroll anti-CD38 naive RRMM patients from DL4 and onwards.
• Part B and the last cohort(s) of Part A: (1) participant has received at least 3 prior lines of therapy for multiple myeloma, or at least 2 prior line of therapy if at least 1 of those lines consisted of 2 or more multi-agent regimens (eg, multi-agent induction regimen with autologous stem cell transplantation, followed by maintenance regimen). (2) Prior therapy for multiple myeloma has included at least 1 proteasome inhibitor (bortezomib, carfilzomib, ixazomib), at least 1 immunomodulatory agent (lenalidomide, thalidomide, pomalidomide) and at least 1 steroid. (3) Prior therapy has not included an anti-CD38 monoclonal antibody.
• Participant has myeloma disease progression on or after last therapy.
• Participant must have measurable disease as defined as at least one of the following:

• Serum M protein ≥0.5 g/dL (≥5 g/L)
• Urine M protein ≥200 mg/24 hours
• Serum FLC assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum
• FLC ratio (<0.26 or >1.65).
• A male participant must agree to use contraception during the intervention period and for at least 150 days after the last dose of study drug and refrain from donating sperm during this period.
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

• Not a woman of childbearing potential (WOCBP)
• A WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 150 days after the last dose of study intervention.

Exclusion Criteria

• Participant is diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, superficial bladder carcinoma or low risk prostate cancer.
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score >2.
• Participant has a history of Chronic obstructive pulmonary disease (COPD) or asthma.
• Participant has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade ≤1 or baseline (exception: alopecia).
• Participant has congestive heart failure (New York Heart Association) Grade ≥II; cardiac myopathy, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy including anticoagulants, or clinically significant uncontrolled hypertension, QT interval corrected by the Fridericia method >480 msec (Grade ≥2).
• Participant has had acute myocardial infarction within 6 months before first dose of study medication.
• Participant has ongoing sensory or motor neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade ≥3.
• Participant has active autoimmune disease including autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel syndrome, pneumonitis or any chronic condition requiring a higher corticosteroid systemic equivalent than prednisone 10 mg daily.
• Known acquired immunodeficiency syndrome (AIDS) or related illnesses or human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or to have active hepatitis A, B (defined as a known positive hepatitis B surface antigen (HBsAg) result or positive HepB DNA), or C (defined as a known quantitative hepatitis C [HCV] ribonucleic acid RNA results greater than the lower limits of detection of the assay or positive HCV antigen) infection.
• Participant has positive Coombs test at baseline.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

City of Hope Site Number : 8400002

Duarte, California, United States

Dana Farber Cancer Institute Site Number : 8400003

Boston, Massachusetts, United States

Mayo Clinic of Rochester Site Number : 8400005

Rochester, Minnesota, United States

UNC Chapel Hill Site Number : 8400006

Chapel Hill, North Carolina, United States

Froedtert Hospital & Medical College of Wisconsin Site Number : 8400004

Milwaukee, Wisconsin, United States

Investigational Site Number : 2030002

Brno, , Czechia

Investigational Site Number : 2030003

Ostrava - Poruba, , Czechia

Investigational Site Number : 2030001

Prague, , Czechia

Investigational Site Number : 2500001

Toulouse, , France

Investigational Site Number : 3000001

Athens, , Greece

Investigational Site Number : 7240001

Salamanca, Salamanca, Spain

Investigational Site Number : 1580001

Taipei, , Taiwan

Countries

United States; Czechia; France; Greece; Spain; Taiwan

References

Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos MA, Huang SY, Spicka I, Chhabra S, Lichtman E, Mateos MV, Kanagavel D, Zhao L, Guillemin-Paveau H, Mace S, van de Velde H, Richardson PG. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2024 Nov;113(5):593-605. doi: 10.1111/ejh.14270. Epub 2024 Jul 12.

Reference Type: BACKGROUND

PMID: 38993150 (View on PubMed)

Related Links

https://www.trialsummaries.com/Study/StudyDetails?id=25358&tenant=MT_SNY_9011

TED16132 Plain Language Results Summary

Other Identifiers

U1111-1223-4410

Identifier Type: REGISTRY

Identifier Source: secondary_id

2019-001018-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TED16132

Identifier Type: -

Identifier Source: org_study_id